We are live on
!
Find out more
Mackenzie Financial Portfolio holdings
AUM
$83.3B
1-Year Est. Return
31.19%
This Fund
S&P 500
This Quarter
Est. Return
+11.13%
1 Year Est. Return
+31.19%
3 Year Est. Return
+75.49%
5 Year Est. Return
+99.03%
10 Year Est. Return
+295.58%
AUM
$77.2B
AUM Growth
+$6.86B
(+9.7%)
Cap. Flow
+$485M
Cap. Flow
% of AUM
0.63%
Top 10 Holdings %
Top 10 Hldgs %
23.5%
Holding
1,822
New
156
Increased
763
Reduced
547
Closed
123
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRSH
Marsh
MRSH
|
+$351M |
| 2 |
NVIDIA
NVDA
|
+$298M |
| 3 |
EMA
Emera Inc
EMA
|
+$231M |
| 4 |
Amazon
AMZN
|
+$177M |
| 5 |
FirstService
FSV
|
+$128M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$239M |
| 2 |
Aon
AON
|
+$236M |
| 3 |
Restaurant Brands International
QSR
|
+$199M |
| 4 |
Accenture
ACN
|
+$136M |
| 5 |
Oracle
ORCL
|
+$126M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 22.09% |
| 2 | Technology | 21.8% |
| 3 | Industrials | 11.13% |
| 4 | Healthcare | 8.33% |
| 5 | Energy | 7.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
951
PTC Therapeutics
PTCT
$6.18B
| $1.28M | ﹤0.01% |
26,286
+194
| +0.7% | +$9.21K |
|
|
APLS
952
DELISTED
Apellis Pharmaceuticals
APLS
| $1.28M | ﹤0.01% |
74,165
+32,632
| +79% | +$604K |
|
953
Primerica
PRI
$10.1B
| $1.28M | ﹤0.01% |
4,676
| – | – |
|
954
Lifestance Health
LFST
$4.15B
| $1.28M | ﹤0.01% |
246,843
+45,892
| +23% | +$275K |
|
955
Jefferies Financial Group
JEF
$12.7B
| $1.26M | ﹤0.01% |
23,091
-2,910
| -11% | -$144K |
|
956
Extreme Networks
EXTR
$3.8B
| $1.25M | ﹤0.01% |
69,798
+696
| +1% | +$10.3K |
|
957
Protagonist Therapeutics
PTGX
$8.55B
| $1.24M | ﹤0.01% |
22,457
-241
| -1% | -$11.6K |
|
|
USAS
958
Americas Gold and Silver
USAS
$1.24B
| $1.24M | ﹤0.01% |
613,760
-640,000
| -51% | -$1.03M |
|
959
Transportadora de Gas del Sur
TGS
$4.48B
| $1.24M | ﹤0.01% |
+47,700
| New | +$1.31M |
|
960
BridgeBio Pharma
BBIO
$16.4B
| $1.23M | ﹤0.01% |
28,390
+9,274
| +49% | +$337K |
|
961
Valmont Industries
VMI
$8.81B
| $1.22M | ﹤0.01% |
3,724
-889
| -19% | -$273K |
|
962
Avantor
AVTR
$9.73B
| $1.22M | ﹤0.01% |
90,340
-21,139
| -19% | -$289K |
|
963
Evercore
EVR
$11.8B
| $1.21M | ﹤0.01% |
4,478
| – | – |
|
964
TKO Group
TKO
$14B
| $1.2M | ﹤0.01% |
6,619
+4,460
| +207% | +$716K |
|
965
Nature's Sunshine
NATR
$362M
| $1.19M | ﹤0.01% |
80,591
+57,736
| +253% | +$780K |
|
966
Academy Sports + Outdoors
ASO
$3.04B
| $1.19M | ﹤0.01% |
26,551
+2,060
| +8% | +$85.4K |
|
967
Ardagh Metal Packaging
AMBP
$2.96B
| $1.19M | ﹤0.01% |
+277,949
| New | +$1.01M |
|
968
Ally Financial
ALLY
$13.1B
| $1.19M | ﹤0.01% |
30,510
+6,715
| +28% | +$233K |
|
969
Casey's General Stores
CASY
$32.1B
| $1.19M | ﹤0.01% |
+2,324
| New | +$1.07M |
|
970
Jackson Financial
JXN
$8.4B
| $1.18M | ﹤0.01% |
13,331
+4,405
| +49% | +$357K |
|
971
CoreCivic
CXW
$2.94B
| $1.18M | ﹤0.01% |
56,161
-32,941
| -37% | -$710K |
|
972
Synaptics
SYNA
$4.05B
| $1.18M | ﹤0.01% |
+18,217
| New | +$1.07M |
|
973
NovoCure
NVCR
$1.77B
| $1.18M | ﹤0.01% |
+66,152
| New | +$1.15M |
|
974
Fortuna Silver Mines
FSM
$2.54B
| $1.18M | ﹤0.01% |
179,654
-481,907
| -73% | -$2.99M |
|
|
BRY
975
DELISTED
Berry Corp
BRY
| $1.17M | ﹤0.01% |
424,169
+266,941
| +170% | +$713K |
|
Similar funds
Mackenzie Financial's Q2 2025 Portfolio in Review
As of Q2 2025, Mackenzie Financial held 1,822 positions worth $77.2B, up 9.7% from $70.3B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Mackenzie Financial's Q2 2025 filing shows 156 new, 763 increased, 547 reduced and 123 closed positions. Its largest new stake was Emera Inc: 5,154,300 shares worth $236M. The largest sale was Thermo Fisher Scientific, an estimated $239M.
By sector, the portfolio is most concentrated in Financials at 22% of assets, down from 22% a quarter earlier, followed by Technology and Industrials.
- Mackenzie Financial's largest Q2 2025 buy was Emera Inc: 5,154,300 shares worth $236M.
- Mackenzie Financial added most to Marsh in Q2 2025, an estimated $351M increase.
- Mackenzie Financial's biggest Q2 2025 reduction was Thermo Fisher Scientific, cutting an estimated $239M.
- Mackenzie Financial fully exited Dick's Sporting Goods in Q2 2025, selling an estimated $17.9M.
- Mackenzie Financial's ten largest holdings make up 23% of its $77.2B portfolio in Q2 2025.
- Mackenzie Financial opened 156 new positions and closed 123 in Q2 2025.
- Mackenzie Financial's portfolio value rose 9.7% quarter-over-quarter to $77.2B.
Based on Mackenzie Financial's 13F filing for Q2 2025, filed 13 Aug 2025.